Rhenman & Partners Asset Management’s Kura Oncology KURA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.49M	Buy	591,500 +320,000	+118%	+$3.02M	0.61%	62
2026 Q1	$2.21M	Sell	271,500 -600,500	-69%	-$5.16M	0.27%	79
2025 Q4	$9.06M	Buy	872,000 +382,000	+78%	+$4.01M	0.85%	48
2025 Q3	$4.34M	Buy	490,000 +240,000	+96%	+$1.71M	0.48%	61
2025 Q2	$1.44M	Buy	250,000 +55,000	+28%	+$337K	0.18%	79
2025 Q1	$1.29M	Sell	195,000 -119,526	-38%	-$931K	0.15%	78
2024 Q4	$2.74M	Buy	314,526 +148,000	+89%	+$2.13M	0.28%	73
2024 Q3	$3.25M	Hold	166,526	–	–	0.26%	78
2024 Q2	$3.43M	Hold	166,526	–	–	0.33%	69
2024 Q1	$3.55M	Buy	+166,526	New	+$3.24M	0.34%	59

Other funds holding KURA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Rhenman & Partners Asset Management's KURA Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Kura Oncology (KURA) stake by 118% in Q2 2026, buying an estimated $3.02M and bringing the position to 591,500 shares worth $6.49M. The position accounts for 0.61% of the portfolio, ranked #62.

Rhenman & Partners Asset Management first reported a position in KURA in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.06M in Q4 2025. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

Rhenman & Partners Asset Management held 591,500 shares of Kura Oncology worth $6.49M as of Q2 2026.
Rhenman & Partners Asset Management bought 320,000 Kura Oncology shares in Q2 2026, an estimated $3.02M.
Kura Oncology made up 0.61% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #62 holding.
Rhenman & Partners Asset Management first reported a position in Kura Oncology in Q1 2024 and has held it in 10 quarters since.
Rhenman & Partners Asset Management's Kura Oncology position peaked at $9.06M in Q4 2025.
221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.